Genetic Predisposition to Cancer
|
|
- Julian Anthony
- 5 years ago
- Views:
Transcription
1 Genetic Predisposition to Cancer Elena Castro, MD, PhD Prostate Cancer and GU tumours Unit Spanish National Cancer Research Centre Madrid, Spain
2 Abstract 750O: Early detection of hereditary renal cell cancer by improved evaluation of spontaneous pneumothorax patients Abstract 751O: Prevalence of HOXB13G84E germline mutation in UK prostate cancers; correlation with tumours characteristics and outcomes Abstract 491PD: Lynch-like syndrome: Characterization and comparison with EPCAM deletion carriers Abstract 492PD: Functional analysis of the BRCA1 H1686Q sequence variant: From biology to clinic Abstract 493PD: A survey of genetic counsellors about the need of year olds from families with hereditary breast and ovarian cancer syndrome
3 Abstract 8060P: Genomic alterations in patients showing multiple primary tumors and family history of cancer Abstract 8384P: Contribution of rare germline copy number variants and single nucleotide polymorphisms to familial colorectal cancer Abstract 5253P: A multidisciplinary approach to heredofamilial cancer syndromes: evaluation of the first four years of experience at a Spanish University Hospital Abstract 7924P: Prognosis of BRCA1 and BRCA2-related breast cancers: are there differences?
4 Abstract 750O Early detection of hereditary renal cell cancer by improved evaluation of spontaneous pneumothorax patients Paul C. Johannesma, MD et al
5 Birt-Hogg-Dubé Syndrome Birt Hogg Dubé (BHD) syndrome is an autosomal dominant, hereditary cancer syndrome in which affected individuals are at risk for the development of kidney tumours, pulmonary cysts, pneumotorax and cutaneous fibrofolliculomas % pulmonary cysts 25-30% pneumotorax 75-90% fibrofolliculomas 25-30% renal cancer
6 How frequent is BHD among patients with a primary SP? Included patients N=42 Thoracic CT N=2 Not eligible due Bullous emphysema Included patients N=40 Negative family history PSP Positive family history PSP FLCN mutation analysis Dermatological examination FLCN mutation analysis Dermatological examination Pathogenic mutation Pathogenic mutation Renal MRI Renal MRI Family counseling Family counseling September Johannesma 2014, PC, Reinhard Madrid, R, Kon Spain Y, et al. The prevalence of Birt-Hogg-Dubé syndrome among patients with apparently primary SP. Respirology (in revision) esmo.org
7 How frequent is BHD among patients with a primary SP? 7-9% of SP carry a germline FLCN mutation - Ren et al: 10/102 patients with SP - Johannesma: 3/42 patients with SP Thoracic CT Included patients N=42 N=2 Not eligible due Bullous emphysema Included patients N=40 Negative family history PSP Positive family history PSP FLCN mutation analysis Dermatological examination FLCN mutation analysis Dermatological examination Pathogenic mutation Pathogenic mutation Renal MRI Renal MRI Family counseling Family counseling September Johannesma 2014, PC, Reinhard Madrid, R, Kon Spain Y, et al. The prevalence of Birt-Hogg-Dubé syndrome among patients with apparently primary SP. Respirology (in revision) esmo.org
8 Evaluation of clinical and radiological characteristics among 200 FLCN mutation carriers in BHD 55 families. FLCN + N=200 RCC: N=19 SP: N=60 28/55 families (51%) 1 patient with SP RCC + SP in family: N=15* * Including 7 patients with both RCC and SP So far detection of BHD through SP resulted in 15 RCC patients in our cohort with mean FU of 5 years (1-10)
9 Current advice if BHD is detected 1. Counseling family on pathogenic mutation 2. Follow up mutation carriers with MRI and/or US
10 Current advice if BHD is detected 1. Counseling family on pathogenic mutation 2. Follow up mutation carriers with MRI and/or US FLCN mutation carriers (Houweling AC, et al. Br. J. Cancer 2011; 105: ) 2. Two new cases found during follow up (mean: 5 years follow up) 3. Extrapolating (2/115)x100 = 1.74 new cases per 5 years follow up 4. 0,30 new cases / 100 cases / year 5. 3 new cases of RCC /1000 cases/ year
11 Theoretical extrapolation current data: 1. Screening for pathogenic FLCN mutation of 3.6 patients per BHD family 2. Diagnosing 100 (new) families > 360 pathogenic FLCN mutation carriers 3. At age 70; 16-25%* lifetime risk to develop RCC will lead to new RCC patients * In both studies the observation period is limited and % is based on limited observation Houweling AC, Gijezen LM, et al. Renal cancer and pneumothorax risk in BHDS; an analysis of 115 FLCN mutation carriers from 35 BHD families. Br. J. Cancer 2011; 105: Toro JR, Pautler SE, Stewart L, et al. Lung cysts, spontaneous pneumothorax and genetic associations in 89 families with BHD. Am J Respir Crit Care Med. 2007;175:
12 Flowchart for spontaneous pneumothorax Spontaneous pneumothorax
13 Flowchart for spontaneous pneumothorax Spontaneous pneumothorax - RCC in medical history? - Familial SP - Familial RCC Thoracic CT: Basal Lung cysts?
14 Flowchart for spontaneous pneumothorax Spontaneous pneumothorax - RCC in medical history? - Familial SP - Familial RCC + FLCN mutation analysis Thoracic CT: Basal Lung cysts? +
15 Flowchart for spontaneous pneumothorax Spontaneous pneumothorax - RCC in medical history? - Familial SP - Familial RCC + FLCN mutation analysis + Thoracic CT: Basal Lung cysts? + Family counseling Renal MRI Dermatological consultation
16 Conclusion In our pilot study 7.5% of all SP caused by pathogenic FLCN mutation Including (low dose) thoracic CT can lead to identification BHD families Annual renal imaging offered to affected relatives > detection RCC Limited period of observation leads to detection of RCC in early stage
17 UK 64m population Incidence of pneumotorax: 24 / / year (men) 10/ /year (women) 11,520 PSP/year If 3 RCC/1000 pneumothorax:.35 new cases /year RCC/ year.0.34% of all cases SPAIN 46.5m population Incidence of pneumothorax: 20/ /year (men) 6/ /year (women) 6,975 PSP/year If 3 RCC/1000 pneumothorax: 20 new cases/year RCC/ year 0.44% of all cases
18 330 CT scans to diagnose 1 RCC
19 330 CT scans to diagnose 1 RCC - Larger studies, more relatives, longer screening periods - Better definition of patients that should undergo CT
20 Can we justify a CT scan for all SP based on this study? 330 CT scans to diagnose 1 RCC - Larger studies, more relatives, longer screening periods - Better definition of patients that should undergo CT
21 Abstract 751O Prevalence of HOXB13 G84E germline mutation and prostate cancer risk in the UK Christos Mikropoulos MD et al
22 Screening of 8652 PrCa cases (UKGPCS)and 5252 controls (ProtecT) HOXB13 G84E identified in 0.5% of healthy controls vs. 1.5% of PrCa OR=2.93 (95%CI: ) relative risk of PrCa OR=4.53 (95%CI: ) relative risk of familial PrCa OR=3.11(95%CI:1.98-5) relative risk of early-onset PrCa (under 55 years)
23 Patients characteristics Abstract 751O
24 Patients characteristics Abstract 751O
25 Survival Data No detrimental impact on overall and prostate cancer specific survival Overall Survival Prostate Cancer Specific Survival controls G84E ca
26 HOXB13 G84E is a rare but recurrent germline mutation associated to familial PrCa (Ewing et al, N Engl J Med, 2012) Xu et al, Hum Genet, 2013
27 Shang et al, Eu Urol 2013
28 Shang et al, Eu Urol 2013
29 Mutation present in 1.5% of PrCa cases: 134 carriers Based on PSA, Gleason, TNM most cases had an intermediate risk of relapse» 5 years CSS is 95%
30 Mutation present in 1.5% of PrCa cases: 134 carriers Based on PSA, Gleason, TNM most cases had an intermediate risk of relapse» 5 years CSS is 95% No impact on survival Median follow-up and events (deaths) not disclosed Short follow-up and few events to see a difference
31 OR=3.11 relative risk of early-onset PrCa (under 55 years) However, no differences on age at diagnosis between carriers and non-carriers were seen in this series
32 HOXB13 Increased risk of PrCa (OR , depending on population) (Shang et al Eu Urol, 2013) Early onset Family History (Ewing et al, N Eng J Med, 2012) (Shang et al, Eu Urol, 2013) No association with aggressiveness has been seen Pseudohyperplastic-type features and markedly low prevalence of ERG + with increased prevalence of SPINK1 cancers (Smith S et al, Am J Surg Pathol, 2014) Impact on PrCa outcomes remains unknown
33
34 26-30 September 2014, Madrid, Spain Morrison et al; Oncologist, esmo.org 2010
35 Chromophobe Chromophobe + oncocytic Mixed pattern Bilateral. Multifocal Clinical implications of FLCN mutations still unknown Treatment as sporadic RCC Nephron sparing surgery Systemic for Metastatic Role of Adjuvant treatment? Lineham et al, Genome research, 2012
36 26-30 September 2014, Madrid, Spain Menko et al, Lancet Oncol, esmo.org 2010
Case Report Bilateral Renal Tumour as Indicator for Birt-Hogg-Dubé Syndrome
Case Reports in Medicine, Article ID 618675, 4 pages http://dx.doi.org/10.1155/2014/618675 Case Report Bilateral Renal Tumour as Indicator for Birt-Hogg-Dubé Syndrome P. C. Johannesma, 1 R. J. A. van Moorselaar,
More informationCase Based Urology Learning Program
Case Based Urology Learning Program Resident s Corner: UROLOGY Case Number 18 CBULP 2011 041 Case Based Urology Learning Program Editor: Associate Editors: Manager: Case Contributors: Steven C. Campbell,
More informationClinical and genetic study of a large Chinese family presented with familial spontaneous pneumothorax
Original Article Clinical and genetic study of a large Chinese family presented with familial spontaneous pneumothorax Huajie Xing, Yanguo Liu, Guanchao Jiang, Xiao Li, Yanyan Hou, Fan Yang, Jun Wang Department
More informationHereditary Prostate Cancer: From Gene Discovery to Clinical Implementation
Hereditary Prostate Cancer: From Gene Discovery to Clinical Implementation Kathleen A. Cooney, MD MACP Duke University School of Medicine Duke Cancer Institute (No disclosures to report) Overview Prostate
More informationRenal Cell Carcinoma: Genetics & Imaging Srinivasa R Prasad University of Texas San Antonio
Renal Cell Carcinoma: Genetics & Imaging Srinivasa R Prasad University of Texas HSC @ San Antonio No financial disclosures Acknowledgements Dr. Peter Choyke, NIH My Gurus @ MIR, MGH 2004 WHO Taxonomy of
More informationCase 1 PLEASE TURN OFF YOUR CELL PHONES 3/28/2017. Disclosure of Relevant Financial Relationships. Disclosure of Relevant Financial Relationships
PLEASE TURN OFF YOUR CELL PHONES Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME disclose
More informationEnterprise Interest Nothing to declare
Enterprise Interest Nothing to declare Pulmonary Pathology of Birt-Hogg-Dubé (BHD) Syndrome Mitsuko FURUYA, Ikuma KATO, Reiko TANAKA, Yukio NAKATANI. Yokohama City University, Japan Chiba University, Japan
More informationA Japanese Family with Multiple Lung Cysts and Recurrent Pneumothorax: A Possibility of Birt-Hogg-Dubé Syndrome
CASE REPORT A Japanese Family with Multiple Lung Cysts and Recurrent Pneumothorax: A Possibility of Birt-Hogg-Dubé Syndrome Hiroshi Ishii 1, Hiroaki Oka 1, Yuka Amemiya 1, Atsuko Iwata 1, Satoshi Otani
More informationFeasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015
Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015 Study Name Feasibility of Patient Population for proposed
More informationProstateGene What is hereditary prostate cancer? What are genes?
ProstateGene ProstateGene What is hereditary prostate cancer? Prostate cancer is the most common cancer among men in the UK. Unfortunately, 1 in 8 men will be diagnosed with prostate cancer, with 75% being
More informationBRCA 1/2. Breast cancer testing THINK ABOUT TOMORROW, TODAY
BRCA 1/2 Breast cancer testing THINK ABOUT TOMORROW, TODAY 5 10% of patients with breast and/or ovarian cancer have a hereditary form1. For any individual carrying a mutation in BRCA1 or BRCA2, the lifetime
More informationCase Based Learning Program
Case Based Learning Program The Department of Urology Glickman Urological & Kidney Institute Cleveland Clinic Case Number 5 CBULP 2010 001 Case Based Urology Learning Program Editor: Associate Editor:
More informationProstateGene GeneHealth UK
ProstateGene GeneHealth UK ProstateGene What is hereditary Prostate cancer? Prostate cancer is the most common cancer among men in the UK. Unfortunately, 1 in 8 men will be diagnosed with prostate cancer,
More informationAllinaHealthSystems 1
Overview Biology and Introduction to the Genetics of Cancer Denise Jones, MS, CGC Certified Genetic Counselor Virginia Piper Cancer Service Line I. Our understanding of cancer the historical perspective
More informationGYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome
More informationCase Report Staged, Open, No-Ischemia Nephron-Sparing Surgery for Bilateral-Multiple Kidney Tumors in a Patient with Birt-Hogg-Dubé Syndrome
Case Reports in Medicine Volume 2012, Article ID 639629, 6 pages doi:10.1155/2012/639629 Case Report Staged, Open, No-Ischemia Nephron-Sparing Surgery for Bilateral-Multiple Kidney Tumors in a Patient
More informationGYNplus. genetic testing for hereditary ovarian and/or uterine cancer
GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome
More informationHEREDITY & CANCER: Breast cancer as a model
HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic
More informationClinical Cancer Genetics
Clinical Cancer Genetics Lisen Axell, MS, CGC University of Colorado Cancer Center Individuals with cancer Making surgical decisions (lump vs. mast) Making treatment decisions (XRT) Concerns for additional
More informationCancer statistics (US)
Disclosure I have no financial relationships to disclose Biology and Introduction to the Genetics of Cancer Vickie Matthias Hagen, MS, CGC Certified Genetic Counselor Virginia Piper Cancer Service Line
More informationBRCAplus. genetic testing for hereditary breast cancer
BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial
More informationAssessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18
Assessment and Management of Genetic Predisposition to Breast Cancer Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Overview The role of the Cancer Genetics team NICE guidelines for Familial Breast
More informationGermline Genetic Testing for Breast Cancer Risk
Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)
More informationUpdates in Cancer Genetics & Genomics
Updates in Cancer Genetics & Genomics Jennifer R. Klemp, PhD, MPH, MA Associate Professor of Medicine, Division of Clinical Oncology Director, Cancer Survivorship Co-Program Leader, Cancer Prevention and
More informationGenomics and Genetic Testing. Copyright 2017 Myriad Genetics, Inc., all rights reserved.
Genomics and Genetic Testing Copyright 2017 Myriad Genetics, Inc., all rights reserved. www.myriad.com Why is genetic testing important to you? Impact on immediate treatment decisions Identify risks for
More informationSo, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes.
Hello. My name is Maureen Mork and I m a Certified Genetic Counselor in the Clinical Cancer Genetics Program at The University of Texas MD Anderson Cancer Center. I ll be lecturing today on the Cancer
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationOverview of peculiarities and therapeutic options for patients with breast cancer and a BRCA germline mutation
Overview of peculiarities and therapeutic options for patients with breast cancer and a BRCA germline mutation Dr Niklas Loman PhD MD Consultant oncologist Skåne University Hospital Lund, Suecia Prognosis
More informationSpontaneous pneumothorax as indicator for Birt-Hogg-Dubé syndrome in paediatric patients
Johannesma et al. BMC Pediatrics 2014, 14:171 CASE REPORT Open Access Spontaneous pneumothorax as indicator for Birt-Hogg-Dubé syndrome in paediatric patients Paul C Johannesma 1, Ben EEM van den Borne
More informationCentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor Banner MD Anderson Cancer Center Objectives Describe the role of genetic counseling and genetic testing in patient
More informationSpontaneous pneumothorax as indicator for Birt- Hogg-Dubé syndrome in paediatric patients
Spontaneous pneumothorax as indicator for Birt- Hogg-Dubé syndrome in paediatric patients Paul C Johannesma 1 Email: p.johannesma@vumc.nl Ben EEM van den Borne 2 Email: ben.vd.borne@catharinaziekenhuis.nl
More informationGuidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer
Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%
More informationBRCA2 gene. Associated Syndrome Name: Hereditary Breast and Ovarian Cancer syndrome (HBOC) BRCA2 Summary Cancer Risk Table. BRCA2 gene Overview
BRCA gene Associated Syndrome Name: Hereditary Breast and Cancer syndrome (HBOC) BRCA Summary Cancer Risk Table Male Breast GENETIC RISK Female Breast Elevated Risk Elevated Risk BRCA gene Overview Hereditary
More informationThe Role of genetic Testing for Inherited Prostate Cancer Risk
FOIU July 2018 The Role of genetic Testing for Inherited Prostate Cancer Risk Leonard G. Gomella, MD Chairman, Department of Urology Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia,
More informationLynch Syndrome. Angie Strang, PGY2
Lynch Syndrome Angie Strang, PGY2 Background Previously hereditary nonpolyposis colorectal cancer Autosomal dominant inherited cancer susceptibility syndrome Caused by defects in the mismatch repair system
More informationOncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
More informationProactive Patient Paves the Way for Genetic Testing of Eight Family Members
CASE STUDY Proactive Patient Paves the Way for Genetic Testing of Eight Family Members Quick Summary Samar Mohite * was diagnosed with colon adenocarcinoma at the age of 49 years. Genetic counselling was
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationGenetics of Pancreatic Cancer. October 6, If you experience technical difficulty during the presentation:
Genetics of Pancreatic Cancer October 6, 2016 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only: 1-408-435-7088
More informationClasificación Molecular del Cáncer de Próstata. JM Piulats
Clasificación Molecular del Cáncer de Próstata JM Piulats Introduction The Gleason score is the major method for prostate cancer tissue grading and the most important prognostic factor in this disease.
More informationFellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018
Fellow GU Lecture Series, 2018 Prostate Cancer Asit Paul, MD, PhD 02/20/2018 Disease Burden Screening Risk assessment Treatment Global Burden of Prostate Cancer Prostate cancer ranked 13 th among cancer
More informationDisclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1
Disclosure Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-1 Case Presentation A 43 year old male, with partial nephrectomy for a right kidney mass 2013 MFMER slide-2 2013
More informationManagement of BRCA mutation carriers
Management of BRCA mutation carriers Clinical Case Presentation Shani Paluch-Shimon, MBBS, MSc Head, Breast Cancer Service for Young Women Oncology Institute Sheba Medical Center, Israel esmo.org DISCLOSURES
More informationInformation for You and Your Family
Information for You and Your Family What is Prevention? Cancer prevention is action taken to lower the chance of getting cancer. In 2017, more than 1.6 million people will be diagnosed with cancer in the
More informationBHD mutations, clinical and molecular genetic investigations of Birt Hogg Dubé syndrome: a new series of 50 families and a review of published reports
BHD mutations, clinical and molecular genetic investigations of Birt Hogg Dubé syndrome: a new series of 50 families and a review of published reports J R Toro, 1 M-H Wei, 1,2 G M Glenn, 1 M Weinreich,
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationWELCOME. Taking Care of Your Health. April 30, 8 am to noon
WELCOME Taking Care of Your Health April 30, 8 am to noon Cancer: Know Your Risk Emily Kuchinsky, MS, CGC, Certified Genetic Counselor Sporadic Cancer Lifetime Probability- Women Family Cluster Risk factors
More informationPrimary Care Approach to Genetic Cancer Syndromes
Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
More informationMedical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011
Medical Policy Manual Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Date of Origin: January 27, 2011 Section: Genetic Testing Last Reviewed Date: July 2014 Policy No: 02 Effective
More informationCancer Genomics 101. BCCCP 2015 Annual Meeting
Cancer Genomics 101 BCCCP 2015 Annual Meeting Objectives Identify red flags in a person s personal and family medical history that indicate a potential inherited susceptibility to cancer Develop a systematic
More informationDoes Cancer Run in Your Family?
Does Cancer Run in Your Family? Nancie Petrucelli, MS, CGC Clinical Assistant Professor Certified Genetic Counselor/Coordinator Cancer Genetic Counseling Service Karmanos Cancer Institute Wayne State University
More informationGenetic testing for hereditary cancer
Genetic testing for hereditary cancer THE GENETICS OF HEREDITARY CANCER About half of all men and one-third of all women in the US will develop cancer during their lifetimes. Approximately 5% to 10% of
More informationMultidisciplinary approach to Young Breast Cancer Nursing. Department of Surgery, Soonchunhyang University, Cheonan Hospital Eunju Lee
Multidisciplinary approach to Young Breast Cancer Nursing Department of Surgery, Soonchunhyang University, Cheonan Hospital Eunju Lee I have nothing to disclose. No relevant financial relationships with
More informationReview on Tumour Doubling Time (DT) To review the studies that measuring the actual tumour doubling time for human cancers.
Review on Tumour Doubling Time (DT) Objective To review the studies that measuring the actual tumour doubling time for human cancers. Methods We searched the Medline database from January 1966 to January
More informationGenetic Testing: who, what, why?
Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk
More informationRole of imaging in RCC. Ultrasonography. Solid lesion. Cystic RCC. Solid RCC 31/08/60. From Diagnosis to Treatment: the Radiologist Perspective
Role of imaging in RCC From Diagnosis to Treatment: the Radiologist Perspective Diagnosis Staging Follow up Imaging modalities Limitations and pitfalls Duangkamon Prapruttam, MD Department of Therapeutic
More informationGuidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationCASE STUDY. Mutation-Specific Testing: Eligibility for PARP Inhibitor Therapy Established. Introduction. Patient Profile.
CASE STUDY Mutation-Specific Testing: Eligibility for PARP Introduction Genetic testing is an emergent diagnostic technique that can provide specific and actionable inputs to the management of cancer therapy.
More informationHereditary Leiomyomatosis and Renal Cell Carcinoma Variant of Reed s Syndrome - A Rare Case Report
American Research Journal of Urology Volume 1, Issue 1, pp:26-30 Case Hereditary Leiomyomatosis and Renal Cell Carcinoma Variant of Reed s Syndrome - A Rare Case Manas Babu, Devesh Bansal, Sony Mehta,
More informationManagement of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
More informationCancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationCorporate Medical Policy Genetic Testing for Breast and Ovarian Cancer
Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_breast_and_ovarian_cancer 8/1997 8/2017
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationColorectal cancer Chapelle, J Clin Oncol, 2010
Colorectal cancer Chapelle, J Clin Oncol, 2010 Early-Stage Colorectal cancer: Microsatellite instability, multigene assay & emerging molecular strategy Asit Paul, MD, PhD 11/24/15 Mr. X: A 50 yo asymptomatic
More informationAre you at risk of Hereditary Cancer? Your Guide to the Answers
Are you at risk of Hereditary Cancer? Your Guide to the Answers What is Hereditary Cancer? The genes we are born with may contribute to our risk of developing certain types of cancer, including breast,
More informationI have ovarian cancer
I have ovarian cancer Everything you need to know about BRCA1/2 gene mutations (Scotland only) 1 An introduction to BRCA1/2 gene mutations BRCA1 and BRCA2 are genes that repair damage in cells and prevent
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationPoblacions amb alt risc de càncer de pàncrees. Quin seguiment hem de fer?
Poblacions amb alt risc de càncer de pàncrees. Quin seguiment hem de fer? T. Macarulla Hospital Vall d Hebrón Actualització en patologia pancreàtica Societat catalana de pàncrees-scpanc 4 Octubre 2016
More information6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017
Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA
More informationComplete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy
Complete Remission is a Reachable Goal in mrcc L. Albiges Institut Gustave Roussy Is complete remission an achievable goal in mrcc? Lessons from observation Lessons from immunotherapy Current status in
More informationBirt-Hogg-Dubé Syndrome with Multiple Cysts and Recurrent Pneumothorax: Pathological Findings
CASE REPORT Birt-Hogg-Dubé Syndrome with Multiple Cysts and Recurrent Pneumothorax: Pathological Findings Makoto Hayashi 1, Noboru Takayanagi 1, Takashi Ishiguro 1, Yutaka Sugita 1, Yoshinori Kawabata
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor/Cancer Risk Counselor Banner Good Samaritan Cancer Screening & Prevention Program Objectives Describe the role
More informationClinical Policy Title: Genetic testing for prostate cancer prognosis
Clinical Policy Title: Genetic testing for prostate cancer prognosis Clinical Policy Number: CCP.1121 Effective Date: January 1, 2015 Initial Review Date: July 16, 2014 Most Recent Review Date: October
More informationThe Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh
The Genetics of Breast Piri L. Welcsh, PhD Research Assistant Professor University of Washington School of Medicine Division of Medical Genetics 1 Genetics of cancer All cancers arise from genetic and
More informationClonal evolution of human cancers
Clonal evolution of human cancers -Pathology-based microdissection and genetic analysis precisely demonstrates molecular evolution of neoplastic clones- Hiroaki Fujii, MD Ageo Medical Laboratories, Yashio
More informationGenetic testing and pancreatic disease
Genetic testing and pancreatic disease February 2 d, 2018 Yale Pancreas Symposium 2018: Multidisciplinary Management of Pancreatic Cancer Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director,
More informationClinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.
Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed
More informationPrevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D.
Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D. Hereditary Cancer Center, Peking University Cancer Hospital 1 Breast cancer
More informationWhat is New in Genetic Testing. Steven D. Shapiro MS, DMD, MD
What is New in Genetic Testing Steven D. Shapiro MS, DMD, MD 18th Annual Primary Care Symposium Financial and Commercial Disclosure I have a no financial or commercial interest in my presentation. 2 Genetic
More informationI have ovarian cancer
I have ovarian cancer Everything you need to know about BRCA1/2 gene mutations (NHS England only) 1 An introduction to BRCA1/2 gene mutations BRCA1 and BRCA2 are genes that repair damage in cells and prevent
More informationAdvice about familial aspects of breast cancer and epithelial ovarian cancer
Advice about familial aspects of breast cancer and epithelial ovarian cancer a guide for health professionals FEBRUARY 2006 These guidelines contain three parts: 1. Information for health professionals
More informationRenal cancer and pneumothorax risk in Birt Hogg Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families
British Journal of Cancer (2011) 105, 1912 1919 All rights reserved 0007 0920/11 www.bjcancer.com Renal cancer and pneumothorax risk in Birt Hogg Dubé syndrome; an analysis of 115 FLCN mutation carriers
More informationExpert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian
Expert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian ANNOUNCER OPEN: Welcome to CME on ReachMD. This segment, entitled Inherited Susceptibility to Cancer: What Do Primary Care Providers
More informationHereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families
Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families What is Hereditary Breast and Ovarian Cancer (HBOC)? Hereditary Breast and Ovarian Cancer is a genetic condition which
More informationSpectrum of Care Options for Women at High Risk for Breast and Ovarian Cancer
Spectrum of Care Options for Women at High Risk for Breast and Ovarian Cancer Sheryl G.A. Gabram, MD, MBA, FACS Professor of Surgery, Emory University Director, High Risk Assessment Program Winship Cancer
More information"Genetic Testing and Genetic Counseling in Prostate Cancer"
National Alliance of State Prostate Cancer Coalitions Webinar Series "Genetic Testing and Genetic Counseling in Prostate Cancer" Leonard G. Gomella, MD Chairman Department of Urology Sidney Kimmel Cancer
More informationWhat we know about Li-Fraumeni syndrome
What we know about Li-Fraumeni syndrome Dr Helen Hanson Consultant in Cancer Genetics St Georges Hospital, South-West Thames Regional Genetics Service History of LFS 1969 Li and Fraumeni describe four
More informationTumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationBowelGene. How do I know if I am at risk? Families with hereditary bowel cancer generally show one or more of the following clues:
BowelGene BowelGene What is hereditary bowel cancer? Bowel cancer (also known as colorectal cancer) is the fourth most common cancer in the UK. Unfortunately 1 in 19 women and 1 in 14 men will develop
More informationRenal and pulmonary Aspects of Birt-Hogg-Dubé syndrome
Renal and pulmonary Aspects of Birt-Hogg-Dubé syndrome Paul Christiaan Johannesma Renal and Pulmonary Aspects of Birt-Hogg-Dubé syndrome. Paul Christiaan Johannesma Thesis, Faculty of Medicine, VU University
More informationWe know that treatments are now targeting genes, but does genetics play a bigger role in cancer outside of that?
Welcome to the 3Ps of Cancer podcast, where we'll discuss prevention, preparedness, and progress in cancer treatments and research. Brought to you by the University of Michigan Rogel Cancer Center. I'm
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationHow does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy
How does histology alter treatment? Cora N. Sternberg, MD, FACP Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Targeting VHL/HIF in Clear Cell RCC VHL Bevacizumab (Antibody)
More informationWhich melanoma patients benefit from genetic testing?
Which melanoma patients benefit from genetic testing? Michael A. Marchetti, MD Assistant Attending, Dermatology Service Memorial Sloan Kettering Cancer Center American Academy of Dermatology Annual Meeting
More information